ObsEva has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021. The biotech company develops and commercializes novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment…
Gynecological imaging startup Illumigyn has raised $33M from investors including Yozma Group Korea and Ubicom Holdings Japan to fund its global expansion. The company’s vision is to disrupt the medical field of gynecology with a complete platform solution featuring the Gynescope System, a new and FDA cleared “gynecology endoscope” and cloud platform service. Illumigyn was founded in Israel by Ran Poliakine and…
Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, has received FDA clearance for Sonata System 2.2, which provides new benefits for facilities, physicians and patients. These benefits include a 20% reduction in the smallest ablation size setting, which greatly increases the ability to treat fibroids in tighter anatomical locations, new software advances that…
Hologic’s Acessa procedure is now covered by Anthem Blue Cross Blue Shield, the second largest health plan in the United States. Anthem has updated its medical policy to cover Radiofrequency Ablation (LAP-RFA), which includes the Acessa procedure for women suffering from uterine fibroids. The updated policy creates access to uterine-preserving care for Anthem’s approximately 40 million members in all 50 states, providing…
AOA Dx has signed an Exclusive License Agreement with Professor H. Uri Saragovi, a Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University, to secure a suite of IP related to utilizing gangliosides for early cancer detection through liquid biopsies. A family of gangliosides function as tumor markers, as they are low or absent…
Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Cigna has released a national coverage policy for treatment of uterine fibroids with the Sonata System. The Sonata System uses radiofrequency energy to ablate fibroids under real time sonography guidance from within the uterine cavity, utilizing the first and only intrauterine ultrasound…
Auransa, an artificial intelligence (AI) company developing precision medicines in areas of unmet medical needs, and Polaris Quantum Biotech (POLARISqb), a quantum drug design company, announced a research collaboration addressing therapeutics for neglected diseases disproportionately affecting women. The partnership seeks to discover treatments that may tackle many such diseases, and their complementary expertise promises to seek solutions that elude medical research. Auransa…
Women’s health company Hologic has announced a new parntership with Cigna, one of the largest global health insurance service companies. Cigna has updated its medical policy to cover Hologic’s Acessa Laparoscopic Radiofrequency Ablation (Lap-RFA) procedure (CPT code 58674) as medically necessary. This new coverage further validates laparoscopic radiofrequency ablation (Lap-RFA) as a standard of care for uterine fibroids. The Acessa procedure can…
